



AstraZeneca

IAP4 Rec'd PCT/PTO 20 DEC 2005

1615

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/524963	Applicant: Tonge et al
371 Filing Date: Not Yet Known	Attorney Docket No.: 100815-1P US
Examiner: Not Yet Assigned	Group Art Unit : 1615
Customer No.: 44992	Confirmation No.: 3567
Title: N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4'-1,3,4-oxadiazol-2-yl)phenylpyridine-3-sulphonamide as an anticancer agent	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 13, 2005

Lucy Padget

Signature
Lucy Padget

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

2nd SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451
USA

Tel +1 781-839-4000
Fax +1 781-839-4500


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the **first Office Action** on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Forms SB08 A and B, and other information contained herein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100815-1P US.

Respectfully submitted,



Name: Lucy Padget
Dated: December 13, 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Form SB08A (1 page)
Documents

